semaglutide approved for mash Wegovy Is Now the Second FDA-Approved Treatment Fibrosis Wegovy becomes first GLP-1RA to

The retatrutide peptide activates GLP-1, GIP, and glucagon receptors together, creating unmatched weight-loss and metabolic benefits in early trials

The FDA labels for weight management formulations explicitly recommend comprehensive lifestyle intervention as part of treatment

During tuberculosis infection, Mycobacterium tuberculosis (MTB) escaping into the macrophage cytosol triggers mitochondrial ROS (mtROS) bursts

(2025) 12:e2413759

The Wegovy maintenance-dose price of 195.10 per month is now the lowest visible public price for semaglutide 2.4 mg in any major European market with full reimbursement

[] These effects are hypothesized to result from reduced maternal food intake and weight, which often accompany GLP-1 usage